Bacterial vaginosis (BV) is a type of vaginal inflammation that occurs when there is an imbalance or depletion of the normal vaginal flora, allowing for other pathogens to begin to grow.
The normal vaginal flora is dynamic and usually inhabited by lactobacilli, which keep it acidic and maintain a protected environment for the human host.
Women in their reproductive years are most likely to get Bacterial Vaginosis, but it can affect women of any age. BV may increase the risk of sexually transmitted infections and cause serious pregnancy complications, including miscarriage and pre-term birth.
Traditional therapy for symptomatic BV has been metronidazole. However, recent studies have shown that recurrent bacterial vaginosis after antimicrobial therapy is a major problem, affecting >50% of patients within one year. Providers are currently in need of a diagnostic tool to not only quickly identify pathogens that cause BV, but also monitor therapy success.
Clinical Solution
Vikor Scientific™ offers the clinician access to one of the most advanced molecular methodologies for pathogen detection, quantification, and resistance gene identification. Vikor delivers rapid and precise results simultaneously with actionable guidance, which incorporates regional sensitivity and susceptibility patterns, medication costs, antibiotic spectrum of activity, and treatment guidance for providers to consider when determining what’s best for their patients.
The end product is a patient-centered, value-based care solution that enables providers to make informed treatment decisions that could avoid inappropriate therapy, excess costs, adverse drug events and the progression of disease.
Clinical Advantages
- Prevents delays in diagnosis and treatment (*results within 24 to 48 hours post specimen arrival to lab)
- Detects polymicrobial infections simultaneously
- Identifies up to 49 antibiotic resistance genes in 13 antibiotic classes including Methicillin, Carbapenem and Vancomycin resistance
- Reduced susceptibility to being affected by concurrent antibiotic therapy
- Can help reduce risks of drug exposure and adverse events
- Can help decrease the progression and spread of infection
- Provides up-to-date regional sensitivity and susceptibility patterns
- Improves selection of narrow-spectrum antibiotics
- Prepares clinicians to make cost-effective treatment decisions
- Easily accessible results (mobile, web-portal or EMR integration)
* Test results could be delayed in some circumstances when there is error in clerical documentation, collections, lab handling, or a delay in shipping.
